Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Urocidin vs Chemo P3B
View:
Post by wussy on Apr 20, 2014 7:30am

Urocidin vs Chemo P3B

Here is an article that may explain why P3B trial would never end.

https://www.thewhig.com/2014/04/18/bladder-cancer-patients-not-receiving-chemotherapy


Wussy
Comment by beechguy on Apr 20, 2014 2:13pm
Great find Wussy. That explains a lot. I could never understand how Endo couldn't fill the trial when the alternative was cystectomy (bladder removal). With only a 5% efficacy for Mytomycin (likely as its a chemo) and so many side effects, why take the chance?? It all makes sense to me now, and gives me a lot more comfort for the path forward for Urocidin. For all of you continuously bashing ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities